FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386099522> ?p ?o ?g. }

• W4386099522 abstract "Lipoxygenases (LOX) transform arachidonic acid (AA, C20:4) and docosahexaenoic acid (DHA, C22:6) into bioactive lipid mediators (LMs) that comprise not only pro-inflammatory leukotrienes (LTs) but also the specialized pro-resolving mediators (SPMs) that promote inflammation resolution and tissue regeneration. The 5-LOX-activating protein (FLAP) is known to provide AA as a substrate to 5-LOX for generating LTs, such as LTB4, a potent chemoattractant and activator of phagocytes. Notably, 5-LOX is also involved in the biosynthesis of certain SPMs, namely, lipoxins and D-resolvins, implying a role of FLAP in SPM formation. FLAP antagonists have been intensively developed as LT biosynthesis inhibitors, but how they impact SPM formation is a matter of debate. Here, we show that FLAP antagonism suppresses the conversion of AA by 5-LOX to LT and lipoxins, while the conversion of DHA to SPM is unaffected. Screening of multiple prominent FLAP antagonists for their effects on LM formation in human M1- and M2-monocyte-derived macrophages by comprehensive LM profiling showed that all nine compounds reduced the production of 5-LOX-derived LTs but increased the formation of SPMs from DHA, e.g., resolvin D5. Some FLAP antagonists, especially those that contain an indole or benzimidazole moiety, even elicited SPM formation in resting M2-monocyte-derived macrophages. Intriguingly, in coincubations of human neutrophils and platelets that produce substantial AA-derived lipoxin and DHA-derived RvD5, FLAP antagonism abolished lipoxin formation, but resolvin D5 levels remained unaffected. Conclusively, antagonism of FLAP suppresses the conversion of AA by 5-LOX to LTs and lipoxins but not the conversion of DHA by 5-LOX to SPM, which should be taken into account for the development of such compounds as anti-inflammatory drugs." @default.
• W4386099522 created "2023-08-24" @default.
• W4386099522 creator A5023008183 @default.
• W4386099522 creator A5045395183 @default.
• W4386099522 creator A5047571275 @default.
• W4386099522 creator A5089874342 @default.
• W4386099522 date "2023-08-23" @default.
• W4386099522 modified "2023-09-27" @default.
• W4386099522 title "Differential impact of 5-lipoxygenase-activating protein antagonists on the biosynthesis of leukotrienes and of specialized pro-resolving mediators" @default.
• W4386099522 cites W1204077956 @default.
• W4386099522 cites W1503616477 @default.
• W4386099522 cites W1536616493 @default.
• W4386099522 cites W1963614163 @default.
• W4386099522 cites W1968792529 @default.
• W4386099522 cites W1971572251 @default.
• W4386099522 cites W1994616470 @default.
• W4386099522 cites W1999783546 @default.
• W4386099522 cites W2013191257 @default.
• W4386099522 cites W2021111392 @default.
• W4386099522 cites W2065297082 @default.
• W4386099522 cites W2072993592 @default.
• W4386099522 cites W2084117223 @default.
• W4386099522 cites W2086093307 @default.
• W4386099522 cites W2087736560 @default.
• W4386099522 cites W2090609282 @default.
• W4386099522 cites W2153202165 @default.
• W4386099522 cites W2514734288 @default.
• W4386099522 cites W2564516757 @default.
• W4386099522 cites W2734973925 @default.
• W4386099522 cites W2738732235 @default.
• W4386099522 cites W2747098918 @default.
• W4386099522 cites W2778372284 @default.
• W4386099522 cites W2792001755 @default.
• W4386099522 cites W2802901067 @default.
• W4386099522 cites W2810811103 @default.
• W4386099522 cites W2914637605 @default.
• W4386099522 cites W2922021750 @default.
• W4386099522 cites W3082774434 @default.
• W4386099522 cites W3093037158 @default.
• W4386099522 cites W3150881341 @default.
• W4386099522 cites W3196809854 @default.
• W4386099522 cites W3197559361 @default.
• W4386099522 cites W3212100771 @default.
• W4386099522 cites W4200366656 @default.
• W4386099522 cites W4211155585 @default.
• W4386099522 cites W4225611066 @default.
• W4386099522 cites W4285405524 @default.
• W4386099522 cites W4291710951 @default.
• W4386099522 cites W4312196279 @default.
• W4386099522 cites W4323073118 @default.
• W4386099522 doi "https://doi.org/10.3389/fphar.2023.1219160" @default.
• W4386099522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37680719" @default.
• W4386099522 hasPublicationYear "2023" @default.
• W4386099522 type Work @default.
• W4386099522 citedByCount "0" @default.
• W4386099522 crossrefType "journal-article" @default.
• W4386099522 hasAuthorship W4386099522A5023008183 @default.
• W4386099522 hasAuthorship W4386099522A5045395183 @default.
• W4386099522 hasAuthorship W4386099522A5047571275 @default.
• W4386099522 hasAuthorship W4386099522A5089874342 @default.
• W4386099522 hasBestOaLocation W43860995221 @default.
• W4386099522 hasConcept C168261976 @default.
• W4386099522 hasConcept C170493617 @default.
• W4386099522 hasConcept C180899940 @default.
• W4386099522 hasConcept C181199279 @default.
• W4386099522 hasConcept C185592680 @default.
• W4386099522 hasConcept C202751555 @default.
• W4386099522 hasConcept C203014093 @default.
• W4386099522 hasConcept C2776042228 @default.
• W4386099522 hasConcept C2776452501 @default.
• W4386099522 hasConcept C2776661833 @default.
• W4386099522 hasConcept C2776914184 @default.
• W4386099522 hasConcept C2778078955 @default.
• W4386099522 hasConcept C2779244956 @default.
• W4386099522 hasConcept C2780415110 @default.
• W4386099522 hasConcept C2780857362 @default.
• W4386099522 hasConcept C37547375 @default.
• W4386099522 hasConcept C553450214 @default.
• W4386099522 hasConcept C55493867 @default.
• W4386099522 hasConcept C86803240 @default.
• W4386099522 hasConcept C88045685 @default.
• W4386099522 hasConcept C90342290 @default.
• W4386099522 hasConcept C95444343 @default.
• W4386099522 hasConcept C98274493 @default.
• W4386099522 hasConceptScore W4386099522C168261976 @default.
• W4386099522 hasConceptScore W4386099522C170493617 @default.
• W4386099522 hasConceptScore W4386099522C180899940 @default.
• W4386099522 hasConceptScore W4386099522C181199279 @default.
• W4386099522 hasConceptScore W4386099522C185592680 @default.
• W4386099522 hasConceptScore W4386099522C202751555 @default.
• W4386099522 hasConceptScore W4386099522C203014093 @default.
• W4386099522 hasConceptScore W4386099522C2776042228 @default.
• W4386099522 hasConceptScore W4386099522C2776452501 @default.
• W4386099522 hasConceptScore W4386099522C2776661833 @default.
• W4386099522 hasConceptScore W4386099522C2776914184 @default.
• W4386099522 hasConceptScore W4386099522C2778078955 @default.
• W4386099522 hasConceptScore W4386099522C2779244956 @default.
• W4386099522 hasConceptScore W4386099522C2780415110 @default.
• W4386099522 hasConceptScore W4386099522C2780857362 @default.
• W4386099522 hasConceptScore W4386099522C37547375 @default.

• next